Search PubMed⌕ Search

Biomedical subjects

B Neumann

Publications and source records attributed to B Neumann.

69 records · Page 4Linked to original sources

Pharmacokinetics of amezinium in rat and dog.

Using 14C-labelled 4-amino-6-methoxy-1-phenyl-pyridazinium methyl sulfate (ameziniummetilsulfate, LU 1631, Regulton), briefly called amezinium, the time course of plasma level in the rat and of blood level and renal excretion rate in the dog has been followed. The distribution of radioactivity in the organism was investigated by autoradiography of whole-animal sections and by quantitative radioactivity determinations in rat tissue as well as by in vitro experiments. From the results we draw the following conclusions: 1. In the two species investigated here, amezinium is almost completely absorbed after enteral administration. In the rat the absorption proceeds with a half-life of 11 min, after a lag phase of 6 min. In the dog, the lag phase is 30-40 min, after which the compound is absorbed with a half-life of 30 min or less. The small intestine appears to be the site of absorption. 2. Amezinium has a high affinity for tissues. Its transport through the cell membrane, in the case of sympathetic neurons and probably also in the case of other chromaffin cells, is mediated by the noradrenaline carrier; in other tissues, for example the liver, a different active transport mechanism, as yet not elucidated, is operating. The placenta and blood-brain barrier are passed only slightly, if at all. In rat blood amezinium distributes between erythrocytes and plasma with a ratio of 2.7:1; the proportion bound to plasma proteins is about 20%. 3. In the rat amezinium is eliminated from the circulation to the extent of about 3/4 by biotransformation; on enteral administration, about 80% is trapped by first-pass metabolism. In the dog biotransformation accounting for about 40% of the elimination is relatively unimportant; the first-pass metabolism is virtually negligible. 4. Amezinium is eliminated by rats about equally with urine and bile, whilst in the dog the predominant proportion is excreted renally. From plasma level curves the terminal half-life t 1/2 (beta) in the rat was found to be 17 h and 21 h after i.v. and p.o. administration, respectively; blood level data and urinary excretion data in the case of the dog gave 5 1/2 (beta) values between 11 h and 20 h. 5. Renal clearance of amezinium in the dog is not constant: initially it is several times greater than the glomerular filtration rate (GFR) decreasing subsequently to about the same magnitude or even below the GFR.

Animals↗

[Pharmacology of "essential" phospholipids (author's transl)].

In an extensive pharmacological screening of "essential" phospholipids (EPL) antilipemic, hepatoprotective, broncholytic, as well as slight choleretic effects were found and the substance decreased capillary permeability. There was practically no influence on other functions or systems including the vegetative system (heart, circulation, respiration).

Animals↗

[The anti-hyperlipemic and anti-atherogenic effect of "essential" phospholipids: a pharmacologic trial].

To prove antilipemic and antiatherogenic effectiveness several animal species were given "essential" phospholipids (EPL) during different experimental procedures. The following actions were studied: 1. Effect of EPL-substance after prophylactic and therapeutic oral administration (dosage: 50, 150, 450 mg/kg bodyweight daily) in rats with acute and subacute hypelipemia induced by triton. 2. Effect of EPL-substance after prophylactic and therapeutic oral administration (dosage: 50, 150, 450, 1800 mg/kg bodyweight daily) in rats with dietetic hypercholesterolemia. 3. Effect of EPL-substance after daily oral administration (dosage: 50, 150, 450 mg/kg bodyweight) on the development of coronary and aortic atherosclerosis and various biochemical parameters in cholesterol-fed cockerels. 4. Effect of EPL-substance after dialy oral administration (dosage: 50, 150, 450 mg/kg bodyweight) on subacute triton-hyperlipemia in mini pigs. Triton-administration causes a greater or smaller increase in all parameters of the lipid metabolism measured. EPL treatment decreases these parameters during therapeutic and prophylactic administration in some cases even reaching normal values. The effect was clearly dose-dependent. EPL inhibit the increase in total lipids in dietetic hypercholesterolemia during therapeutic as well as during prophylactic administration. The effect was clearly dose-dependent in all doses, being statistically significant at the highest dosage level. In cockerels EPL were effective at all dose levels in counteracting the development of coronary atherosclerosis while the effect in atherosclerosis of aorta was less distinct. Except for non-esterified fatty acids, EPL reduced all biochemical parameters measured.

Animals↗

Treatment with dexamethasone alters yawning behavior induced by cholinergic but not dopaminergic agonist.

Because stressful manipulations have been reported to modify drug-induced yawning, the present study investigated the effects of single and repeated treatment with a synthetic glucocorticoid, dexamethasone (DEXA) on apomorphine- and pilocarpine-induced yawning in male rats. Neither single nor repeated treatment with DEXA altered apomorphine-induced yawning. Single administration of DEXA, however, resulted in an increased number of yawns induced by pilocarpine. Conversely, repeated administration of DEXA led to a decreased number of yawns induced by pilocarpine. In conclusion, the present findings show that dopaminergic and cholinergic are distinctly altered by DEXA, in terms of yawning behavior when animals received DEXA.

Animals↗

Trends in adolescent alcohol consumption in Halifax, Nova Scotia--1970-1986.

The drinking behaviours of 1,128 students from grades 7 to 12 in Halifax, Nova Scotia were surveyed and the results were compared to surveys done on similar samples of adolescents in 1970, 1976 and 1983. The survey instruments were self-administered, anonymous questionnaires administered in class groups. In the 1986 survey, while no differences (p greater than .05) in the frequency of drinking episodes exists between males and females, the former group were found to be drinking more heavily. Since 1983, the percentage of drinkers has declined significantly (p less than .05) among both sexes. The percentage of frequent drinkers (once a week or more) and heavy drinking (6+ drinks per sitting, more than once per week) has not changed significantly (p greater than .05) in either sex.

Adolescent↗